Clinical Report: Eliminating SHRM May Improve Visual Outcomes
Overview
The elimination of subretinal hyperreflective material (SHRM) is crucial for enhancing visual outcomes in patients with neovascular age-related macular degeneration (nAMD). Findings from the TENAYA and LUCERNE studies indicate that faricimab demonstrates superior reduction of SHRM compared to aflibercept, which correlates with better vision over time.
Background
Subretinal hyperreflective material (SHRM) is a significant biomarker in nAMD, associated with various pathological components that can adversely affect vision. Understanding and addressing SHRM is essential for optimizing treatment strategies and improving patient outcomes. The recent studies have highlighted the importance of early intervention to eliminate SHRM for better long-term visual prognosis.
Data Highlights
No numerical data provided in the source material.
Key Findings
- SHRM is a critical predictor of visual outcomes in nAMD.
- Faricimab shows a greater reduction in SHRM area and volume compared to aflibercept during the loading phase.
- The presence of SHRM at 12 weeks is predictive of vision over time.
- Eliminating SHRM early is linked to improved vision outcomes.
- SHRM features correlate with outer retinal disruption and visual acuity.
Clinical Implications
Clinicians should prioritize the assessment and management of SHRM in patients with nAMD to enhance visual outcomes. The use of second-generation agents like faricimab may provide superior results in reducing SHRM and improving patient vision.
Conclusion
The findings underscore the importance of targeting SHRM in nAMD treatment to achieve optimal visual outcomes. Continued research and clinical application of these insights are essential for advancing patient care.
References
- Retinal Physician, 2025 -- Heads-Up Surgical Display Systems Come Into Focus
- Glaucoma Physician, 2022 -- Product Spotlight: Setting a New Standard for Visual Field Testing
- Optometric Management, 2026 -- Technology Focus: Digital Tool for Amblyopia Care
- Retinal Physician, 2024 -- Retina Cases: Vision Loss in Combined Hamartoma of the Retina and Retinal Pigment Epithelium
- Non-exudative OCT findings in neovascular AMD - PMC, 2026
- Non-exudative OCT findings in neovascular AMD - PMC
- https://assets.roche.com/f/176330/x/03051bc6ad/pi-vabysmo.pdf
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
